Tumor organoids: feasibility to predict sensitivity to treatment in cancer patients (TUMOROID trial)

Completed

• Conditions: breast); colorectal; disseminated cancer (lung; Metastatic cancer; 10027476

• Registration Number: NL-OMON44690
• Lead Sponsor: ederlands Kanker Instituut

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 665

Inclusion Criteria

- Patients with locally advanced (incurable) or metastatic colorectal, breast or lung (non-small cell) cancer who will start treatment with one of the regimens specified in the protocol.
- Measurable/evaluable disease
- Safe histologic tumor biopsy possible
- WHO 0-2

Exclusion Criteria

-

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>• Area under the (partial) receiver operating characteristics (ROC) curve<br /><br>• Optimal organoid screening test threshold and associated accuracy measures<br /><br>(sensitivity, specificity, positive predictive value, negative<br /><br>predictive value)</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>• Success rate of organoid culture from biopsies of colorectal, breast and lung<br /><br>cancer</p><br>